Bristol-Myers Squibb Company
Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
Last updated:
Abstract:
Provided are methods for clinical treatment of multiple myeloma using an anti-KIR antibody in combination with an anti-CS 1 antibody.
Status:
Grant
Type:
Utility
Filling date:
5 Nov 2014
Issue date:
3 Dec 2019